LXRXLexicon Pharmaceuticals, Inc.

$1.67+40% 1Y

Is it safe?

Flag

Elevated bankruptcy risk: a balance sheet under strain, heavy debt (BB), and big price swings. Everything else is secondary until this clears.

1 flagged, 2 to watch, 2 neutral, 1 without data
SurvivalDistress zone

Elevated financial-distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.

Honest booksGrey zone

In the flagged range only because sales grew fast; the other indices are not Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).

Quality4 / 9

Mixed fundamental signals Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.

Credit gradeBBderived · Jun 30, 2026

Net cash, but unprofitable, speculative. A rule of thumb on leverage, not a credit rating.

Drawdown risk110% volderived · Oct 9, 2026

Large price swings, high volatility. Worst drawdown -98% · now 33% below its 52-week high.

Unless marked, from SEC EDGAR, as of Dec 31, 2025.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Volatilitybottom 4% of the market
Max drawdownbottom 2% of the market

Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.

Can LXRX take a bad year?

Lexicon Pharmaceuticals, Inc. holds $139M more cash than debt, so a bad year is a question about profits, not about lenders.

$139M

Net cash

Net debt / EBITDA
net cash

Net debt / EBITDA · no net borrowings to measure against earnings

Altman Z-score
-7.47

Altman Z-score · distress zone, below 1.8

Debt / equity
0.29×

Debt / equity

Details›
Total debtQ2 2026
$51M
Cash and short-term investments
$191M
Net cash
$139M
EBITDA, trailing twelve months
−$54M
Operating profit, trailing twelve months
−$55M
Debt / equity
0.29×
Annualised volatilitytwo years of daily moves
110%
Worst drawdown on file
−99%
Below its 52-week high
33%

Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.